Covis Pharma Sarl has entered an agreement with sanofi-aventis U.S. and its affiliates to acquire full commercial rights to Nilandron, Plaquenil, Rilutek, Uroxatral, and Kayexalate in the U.S. The products are for prostate cancer, anti-malarial, ALS, Benign Prostatic Hyperplasia (BPH), and dangerously high levels of potassium in the blood, respectively. Together these products had sales of $114.6 million in the U.S. in 2012. Sanofi will retain the existing rights for these products outside the U.S.
 
Covis Pharma will promote these products through its U.S. distributor, Covis Pharmaceuticals, Inc. Sanofi will manufacture and supply the products for Covis Pharma.
 
“We are very pleased to announce the addition of these products to our existing portfolio,” said Jack Davis, chief executive officer of Covis Pharma. “Covis will continue to supply consistent, top quality, branded pharmaceuticals, ensuring that patients receive the therapeutic care they need.”